{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:08:03Z","timestamp":1784203683654,"version":"3.55.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xfre.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:55:15Z","timestamp":1760003715000},"page":"411-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy and ovarian function: bridging reproductive health in oncology clinical trials"],"prefix":"10.1016","volume":"6","author":[{"given":"Sarah C.","family":"Cromack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-627X","authenticated-orcid":false,"given":"Kara N.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfre.2025.09.009_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.xfre.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejca.2020.11.032","article-title":"Cancer survivorship: reproductive health outcomes should be included in standard toxicity assessments","volume":"144","author":"Anderson","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xfre.2025.09.009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104064","article-title":"Immune checkpoint inhibitors as a threat to reproductive function: a systematic review","volume":"188","author":"Tuerxun","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.xfre.2025.09.009_bib4","first-page":"420","article-title":"Reproductive impact of immune checkpoint inhibitor therapy in women with melanoma","volume":"6","author":"Rhodes","year":"2025","journal-title":"F S Rep"},{"key":"10.1016\/j.xfre.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/jnci\/djab111","article-title":"Assessment of ovarian function in phase III (neo)adjuvant breast cancer clinical trials: a systematic evaluation","volume":"113","author":"Cui","year":"2021","journal-title":"J Natl Cancer Inst"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266633412500145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266633412500145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:47:07Z","timestamp":1765446427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266633412500145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S266633412500145X"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2025.09.009","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy and ovarian function: bridging reproductive health in oncology clinical trials","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2025.09.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}